Who Owns Green Cross Company?

Green Cross Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns GC Biopharma?

Understanding company ownership is key to grasping its direction and accountability. GC Biopharma, a South Korean biopharmaceutical firm, has evolved significantly, including rebranding efforts to enhance its global presence.

The company's journey began in 1967 as 'Sudo Microorganism Medical Supplies Co.,' later becoming 'Green Cross' in 1971, then 'GC Pharma' in 2018, and finally 'GC Biopharma' in March 2022 to emphasize its biopharmaceutical focus.

Who owns GC Biopharma?

GC Biopharma is a publicly traded entity on the Korea Exchange (KRX). As of August 18, 2025, its market capitalization stood at $508 million, with 45.4 million shares outstanding. The company reported trailing 12-month revenue of $1.6 billion as of March 31, 2025. Its global reach extends to over 50 countries, positioning it as a major producer of plasma protein and vaccine products, a sector detailed in the Green Cross PESTEL Analysis.

The Green Cross Company, now known as GC Biopharma, began its journey in 1967 as 'Sudo Microorganism Medical Supplies Co.' It later rebranded to 'Green Cross' in 1971, marking a significant step in its evolution.

Founding Visionary

Dr. Young-sup Huh was instrumental in Green Cross's early development. He served as the first CEO and chairman, guiding the company's commitment to South Korea's biopharmaceutical sector.

Research and Development Focus

In 1984, Dr. Huh established the MOGAM Institute for Biomedical Research. This institute was funded by profits from Green Cross Pharmaceuticals, underscoring an early dedication to R&D for societal benefit.

Early Public Offerings

The company's ownership structure began to broaden with its Initial Public Offering (IPO). The holding company, 'GC', went public in 1978, followed by 'GC Pharma' (then GC) in 1989.

Key Product Milestones

A significant early achievement was the development of the world's third Hepatitis B vaccine in 1983. This highlighted the company's focus on producing essential biopharmaceuticals.

Founding Ownership Details

Specific initial equity splits among founders are not publicly detailed. However, the company's vision was clearly demonstrated through its research initiatives and product development.

Corporate Evolution

The transition from 'Sudo Microorganism Medical Supplies Co.' to 'Green Cross' and later to GC Biopharma reflects its growth and evolving business scope over the decades.

While the exact initial ownership percentages of the founders are not publicly disclosed, the company's early history is marked by strategic decisions that shaped its ownership landscape. The IPOs of the holding company 'GC' in 1978 and 'GC Pharma' in 1989 were pivotal moments that transitioned ownership from private hands to a broader public base, making it a publicly traded entity. This move facilitated further investment and growth, allowing the company to expand its reach and impact in the biopharmaceutical industry, as detailed in discussions on the Marketing Strategy of Green Cross.

Key Aspects of Early Ownership

The early ownership of Green Cross was primarily shaped by its founders' vision and subsequent public market entries.

• Founding figure: Dr. Young-sup Huh
• Establishment of MOGAM Institute for Biomedical Research in 1984
• IPO of holding company 'GC' in 1978
• IPO of 'GC Pharma' in 1989
• Focus on biopharmaceutical innovation, including the Hepatitis B vaccine

Green Cross SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership structure of GC Biopharma has seen significant shifts since its establishment. Following the initial public offering of its parent company, GC, in 1978, GC Biopharma itself became publicly traded on the Korea Exchange (KRX) in 1989, distributing ownership among various stakeholders.

GC Biopharma functions as a key subsidiary within a broader corporate framework, with GC (Holding Company) acting as the primary parent entity. This structure includes oversight of other affiliates, such as GC Cell. As of December 31, 2022, GC Biopharma held a 33.28% interest in GC Cell, while GC (the holding company) possessed an 8.48% stake in the same entity. While precise figures for individual insider ownership are not publicly detailed, a common trend in expanding companies is a gradual decrease in insider holdings over time. The company's strategic trajectory has been shaped by these ownership dynamics, including recent initiatives aimed at vertical integration. A notable example is the December 2024 acquisition of ABO Holdings, a move designed to ensure a consistent supply of essential raw materials for its blood products business in the United States. This strategic acquisition underscores a commitment to enhancing control over its supply chain and broadening its international market reach, aligning with efforts to understand the Target Market of Green Cross.

Key Stakeholder Dynamics

Understanding who owns Green Cross involves recognizing the interplay between its holding company, institutional investors, and strategic acquisitions.

• GC (Holding Company) is the primary parent entity.
• Institutional investors represent a significant portion of ownership.
• Strategic acquisitions, like ABO Holdings in December 2024, impact ownership and operational control.
• The company's public trading status on the KRX means ownership is distributed among shareholders.

Green Cross PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

GC Biopharma's governance is steered by its Board of Directors, with Eun-Chul Huh serving as both CEO and Chairman, also holding the CTO position. The board's strategic direction is further shaped by executive directors Jae-Wook Jeong (Head of R&D) and Woong Shin (Head of Production), alongside independent directors Choon-Woo Lee, Ki-Joon Park, Jin-Hee Lee, and Seong-Hoon Shim, all appointed in March 2024.

The General Shareholders' Meeting stands as the ultimate decision-making authority for GC Biopharma, handling critical matters in line with legal frameworks and the company's charter. While the specifics of voting power, such as a one-share-one-vote system, are not detailed, the emphasis on the shareholders' meeting implies a standard approach to common share voting rights. The company's structure includes specialized committees within the Board of Directors, designed to bolster strategic management through delegated authority.

Understanding GC Biopharma's Governance

GC Biopharma's corporate structure is designed to ensure effective management and strategic oversight. The Board of Directors, comprising both executive and independent members, guides the company's operations.

• The CEO and Chairman also serves as the CTO.
• Independent directors bring diverse expertise to the board.
• The General Shareholders' Meeting is the highest decision-making body.
• Specialized committees support strategic management functions.
• Understanding the Mission, Vision & Core Values of Green Cross provides context for board decisions.

Green Cross Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past three to five years, GC Biopharma has undergone significant transformations, including a strategic rebranding and key acquisitions aimed at bolstering its global biopharmaceutical presence. These shifts reflect a dynamic approach to market positioning and supply chain management.

Financially, GC Biopharma reported trailing 12-month revenue of $1.6 billion as of March 31, 2025. While the full year ended December 31, 2024, showed a net loss of KRW 26,280.22 million, the company demonstrated a positive financial trajectory in the second quarter of 2025. Q2 2025 earnings revealed a revenue of ₩500.3 billion, marking a 20% increase from Q2 2024, and a net income of ₩38.0 billion, a substantial improvement from the previous year's loss. Analysts project an average annual revenue growth of 7.3% over the next three years. The successful market entry and rapid inclusion of Alyglo in major U.S. health insurer formularies, beginning July 2024, is anticipated to further enhance valuation in 2025, underscoring the company's strategic expansion and financial recovery efforts.

Strategic Rebranding

The rebranding to GC Biopharma in March 2022 signaled a sharpened focus on rare disease pipelines. This move aimed to solidify its identity as a global biopharmaceutical leader.

Vertical Integration Efforts

The acquisition of ABO Holdings in December 2024 highlights a trend towards vertical integration. This strategy enhances supply chain control, particularly for plasma fractionation raw materials.

Global Partnerships and Expansion

Partnerships with entities like the Thai Red Cross Society and Chong Kun Dang Pharmaceutical demonstrate a commitment to global expansion and product distribution. These collaborations are key to increasing market reach.

Financial Performance and Outlook

Recent financial reports show a strong revenue increase in Q2 2025, with analysts forecasting continued growth. The successful market penetration of Alyglo is a significant factor in this positive outlook.

Green Cross Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔